HIV  	HIV  	 NNP	B-NP
resistance  	resistance  	 NN	O
to  	to  	 TO	O
raltegravir  	raltegravir  	 VB	O
Similar  	Similar  	 JJ	O
to  	to  	 TO	O
all  	all  	 DT	O
antiretroviral  	antiretroviral  	 JJ	B-NP
drugs 	drugs 	 NNS	I-NP
,  	,  	 ,	O
failure  	failure  	 NN	O
of  	of  	 IN	O
raltegravir-based  	raltegravir-based  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
regimens  	regimens  	 NN	I-NP
to  	to  	 TO	O
fully  	fully  	 RB	O
supress  	supress  	 JJ	O
HIV  	HIV  	 NNP	B-NP
replication  	replication  	 VBD	O
almost  	almost  	 RB	O
invariably  	invariably  	 JJ	O
results  	results  	 NNS	O
in  	in  	 IN	O
emergence  	emergence  	 NN	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
resistance  	resistance  	 NN	O
to  	to  	 TO	O
this  	this  	 DT	O
new  	new  	 JJ	O
drug 	drug 	 NN	O
.  	.  	 .	O
HIV  	HIV  	 NNP	B-NP
resistance  	resistance  	 NN	O
to  	to  	 TO	O
raltegravir  	raltegravir  	 NN	B-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
consequence  	consequence  	 NN	O
of  	of  	 IN	O
mutations  	mutations  	 NNS	O
located  	located  	 VBN	O
close  	close  	 RB	O
to  	to  	 TO	O
the  	the  	 DT	O
integrase  	integrase  	 JJ	O
active  	active  	 JJ	O
site 	site 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
can  	can  	 MD	O
be  	be  	 VB	O
divided  	divided  	 VBN	O
into  	into  	 IN	O
three  	three  	 CD	O
main  	main  	 JJ	O
evolutionary  	evolutionary  	 JJ	B-NP
pathways 	pathways 	 NN	I-NP
:  	:  	 :	O
the  	the  	 DT	O
N155H 	N155H 	 NNP	O
,  	,  	 ,	O
the  	the  	 DT	O
Q148R 	Q148R 	 NNP	O
/ 	/ 	 NNP	O
H 	H 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
K  	K  	 NNP	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
Y143R 	Y143R 	 NNP	O
/ 	/ 	 NNP	O
C  	C  	 NNP	O
pathways 	pathways 	 NN	O
.  	.  	 .	O
Each  	Each  	 DT	O
of  	of  	 IN	O
these  	these  	 DT	O
primary  	primary  	 JJ	B-NP
mutations  	mutations  	 NNS	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
accompanied  	accompanied  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
variety  	variety  	 NN	O
of  	of  	 IN	O
secondary  	secondary  	 JJ	B-NP
mutations  	mutations  	 NNS	I-NP
that  	that  	 IN	O
both  	both  	 DT	O
increase  	increase  	 NN	B-NP
resistance  	resistance  	 NN	I-NP
and  	and  	 CC	O
compensate  	compensate  	 VB	O
for  	for  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
loss  	loss  	 NN	O
of  	of  	 IN	O
viral  	viral  	 JJ	B-NP
replicative  	replicative  	 JJ	I-NP
capacity  	capacity  	 NN	I-NP
that  	that  	 WDT	O
is  	is  	 VBZ	O
often  	often  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
primary  	primary  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
mutations 	mutations 	 NNS	I-NP
.  	.  	 .	O
One  	One  	 CD	O
unique  	unique  	 JJ	O
property  	property  	 NN	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
resistance  	resistance  	 NN	O
to  	to  	 TO	O
raltegravir  	raltegravir  	 NN	B-NP
is  	is  	 VBZ	O
that  	that  	 IN	O
each  	each  	 DT	O
of  	of  	 IN	O
these  	these  	 DT	O
different  	different  	 JJ	O
resistance  	resistance  	 NN	B-NP
pathways  	pathways  	 NNS	I-NP
are  	are  	 VBP	O
mutually  	mutually  	 RB	O
exclusive  	exclusive  	 JJ	B-NP
and  	and  	 CC	O
appear  	appear  	 VB	O
to  	to  	 TO	O
evolve  	evolve  	 VB	O
separately  	separately  	 RB	O
on  	on  	 IN	O
distinct  	distinct  	 JJ	O
viral  	viral  	 JJ	B-NP
genomes 	genomes 	 NN	I-NP
.  	.  	 .	O
Resistance  	Resistance  	 NN	O
is  	is  	 VBZ	O
frequently  	frequently  	 RB	O
initiated  	initiated  	 VBN	O
by  	by  	 IN	O
viruses  	viruses  	 NNS	O
carrying  	carrying  	 VBG	B-NP
mutations  	mutations  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
N155H  	N155H  	 JJ	O
pathway 	pathway 	 NN	O
,  	,  	 ,	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
emergence  	emergence  	 NN	O
and  	and  	 CC	O
further  	further  	 JJ	O
dominance  	dominance  	 NN	O
of  	of  	 IN	O
viral  	viral  	 JJ	B-NP
genomes  	genomes  	 NNS	I-NP
carrying  	carrying  	 VBG	I-NP
mutations  	mutations  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
Q148R 	Q148R 	 NNP	O
/ 	/ 	 NNP	O
H 	H 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
K  	K  	 NNP	I-NP
or  	or  	 CC	O
of  	of  	 IN	O
the  	the  	 DT	O
Y143R 	Y143R 	 NNP	O
/ 	/ 	 NNP	O
C  	C  	 NNP	O
pathways 	pathways 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
express  	express  	 VBP	O
higher  	higher  	 JJR	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
resistance 	resistance 	 NN	O
.  	.  	 .	O
Even  	Even  	 RB	O
if  	if  	 IN	O
some  	some  	 DT	O
natural  	natural  	 JJ	O
integrase  	integrase  	 JJ	B-NP
polymorphisms  	polymorphisms  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
part  	part  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
evolution  	evolution  	 NN	B-NP
process 	process 	 NN	I-NP
,  	,  	 ,	O
these  	these  	 DT	O
polymorphisms  	polymorphisms  	 NNS	B-NP
do  	do  	 VBP	O
not  	not  	 RB	O
affect  	affect  	 VB	O
HIV  	HIV  	 JJ	B-NP
susceptibility  	susceptibility  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
absence  	absence  	 NN	B-NP
of  	of  	 IN	I-NP
primary  	primary  	 JJ	I-NP
mutations 	mutations 	 NNS	I-NP
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
all  	all  	 DT	O
HIV-1  	HIV-1  	 NNP	B-NP
subtypes  	subtypes  	 NN	I-NP
and  	and  	 CC	O
groups 	groups 	 NNS	O
,  	,  	 ,	O
together  	together  	 RB	O
with  	with  	 IN	O
HIV-2 	HIV-2 	 NNP	B-NP
,  	,  	 ,	O
are  	are  	 VBP	O
naturally  	naturally  	 RB	O
susceptible  	susceptible  	 JJ	O
to  	to  	 TO	O
raltegravir 	raltegravir 	 VB	O
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
because  	because  	 IN	O
interaction  	interaction  	 NN	O
of  	of  	 IN	O
integrase  	integrase  	 JJ	B-NP
strand  	strand  	 JJ	I-NP
transfer  	transfer  	 NN	I-NP
inhibitors  	inhibitors  	 NN	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
HIV  	HIV  	 NNP	B-NP
integrase  	integrase  	 VBD	O
active  	active  	 JJ	O
site  	site  	 NN	O
is  	is  	 VBZ	O
comparable  	comparable  	 JJ	O
from  	from  	 IN	O
one  	one  	 CD	O
compound  	compound  	 NN	B-NP
to  	to  	 TO	O
another 	another 	 DT	O
,  	,  	 ,	O
raltegravir-resistant  	raltegravir-resistant  	 JJ	B-NP
viruses  	viruses  	 NNS	I-NP
express  	express  	 VBP	O
significant  	significant  	 JJ	O
cross  	cross  	 NN	B-NP
resistance  	resistance  	 NN	I-NP
to  	to  	 TO	O
most  	most  	 RBS	O
other  	other  	 JJ	O
compounds  	compounds  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
new  	new  	 JJ	O
class  	class  	 NN	O
of  	of  	 IN	O
antiretroviral  	antiretroviral  	 JJ	B-NP
drugs 	drugs 	 NNS	I-NP
.  	.  	 .	O
